Breaking News Instant updates and real-time market news.

VIA

Viacom

$25.31

0.175 (0.70%)

, VIAB

Viacom

$22.48

0.44 (2.00%)

18:24
11/14/19
11/14
18:24
11/14/19
18:24

Viacom CEO: The road ahead for the company is very exciting

In an interview on CNBC's Mad Money, Viacom (VIA, VIAB) CEO Bob Bakish said: I'm really pleased with fourth quarter results... Merger with CBS (CBS) poised to close in early December... There are material synergies on both the cost and revenue side for this merger... We are playing all the segments and that is what makes us different... People who say we can't compete in streaming are absolutely wrong... The content market is very frothy.

VIA

Viacom

$25.31

0.175 (0.70%)

VIAB

Viacom

$22.48

0.44 (2.00%)

CBS

CBS

$37.62

0.78 (2.12%)

  • 14

    Nov

  • 14

    Nov

  • 09

    Dec

VIA Viacom
$25.31

0.175 (0.70%)

08/14/19
MACQ
08/14/19
DOWNGRADE
Target $31
MACQ
Neutral
Viacom downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Tim Nollen downgraded Viacom (VIAB) to Neutral from Outperform and keeps a Neutral rating on CBS (CBS) shares after the two companies announced a merger deal with no premium for Viacom following "3 years of on again/off again merger discussions amidst wrenching change in the industry." While he believes the deal's strategic positives outweigh the risks, Nollen said integration might not be easy and that ViacomCBS will still be "small-ish" compared with competitors Comcast (CMCSA) and Disney (DIS). He lowered his price target on Viacom shares to $31 from $37 and cut his price target on CBS shares to $53 from $55.
08/14/19
DBAB
08/14/19
UPGRADE
DBAB
Buy
Viacom upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Bryan Kraft upgraded Viacom (VIAB) to Buy from Hold and raised his price target on the stock to $42 from $33. Yesterday, CBS (CBS) and Viacom announced a definitive agreement to combine in an all-stock merger.
09/24/19
09/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Disney (DIS) was initiated with an Outperform at Wells Fargo, while Netflix (NFLX) was initiated with a Market Perform, and CBS (CBS), Viacom (VIAB, VIA), and Fox Corp. (FOXA) were initiated with Underperform ratings. 2. Merit Medical (MMSI) initiated with an Outperform at Oppenheimer. 3. Global Payments (GPN) reinstated with a Buy at Goldman Sachs. 4. 10x Genomics (TXG) initiated with an Outperform at Evercore ISI. 5. Corcept Therapeutics (CORT) and Strongbridge Biopharma (SBBP) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/19
WELS
10/23/19
NO CHANGE
Target $31
WELS
Underperform
CBS price target lowered to $31 from $40 at Wells Fargo
Wells Fargo analyst Steven Cahall lowered his price target for Underperform-rated CBS (CBS) to $31 from $40, saying the Viacom (VIAB)-CBS S-4 has further reduced his investor confidence. HE tells investors that CBS investors are "frustrated" that it took so long to reset expectations to a new lower normal. The analyst also lowered his price target for Viacom to $23 from $18, saying management's projections in the out years appear disconnected from ecosystem realities.
VIAB Viacom
$22.48

0.44 (2.00%)

10/21/19
LEHM
10/21/19
NO CHANGE
Target $41
LEHM
Equal Weight
Barclays cuts CBS target to $41, Viacom target to $24
Barclays analyst Kannan Venkateshwar cut his price target for CBS (CBS) to $41 from $53 and for Viacom (VIAB) to $24 from $33 while keeping Equal Weight ratings on both names. CBS and Viacom shares have sold off ~25% since their merger announcement on August 13, partly due to deal technicals, Venkateshwar tells investors in a research note. However, the analyst believes the selloffs are also a reflection of the fundamental challenges faced by both companies and skepticism around upside from the deal. The S-4 filing last week is the latest evidence of this struggle with CBS cutting its free cash flow estimates for the next couple years by 30%-40% and Viacom cutting EBITDA by 7%-8% versus consensus, Venkateshwar says. As a result of this revision, CBS may miss its long-term standalone earnings and revenue growth guidance provided at the beginning of this year, he adds.
10/24/19
FBCO
10/24/19
NO CHANGE
Target $52
FBCO
Outperform
CBS price target lowered to $52 from $66 at Credit Suisse
Credit Suisse analyst Douglas Mitchelson lowered his price target for CBS (CBS) to $52 from $66 after reviewing the ViacomCBS S-4 merger filing in detail and considering post-merger announcement management commentary. The analyst does not believe the S-4 disclosures for the separate CBS and Viacom (VIAB) budgets represent the outlook for the combined company based on the likely operating strategies of ViacomCBS management. Further, Mitchelson believes management's focus on programming efficiencies and undertaking only modest investments in streaming services suggests the programming/working capital budgets in the S-4 were too high. He reiterates an Outperform rating on CBS shares.
CBS CBS
$37.62

0.78 (2.12%)

10/25/19
SBSH
10/25/19
NO CHANGE
Target $51
SBSH
Buy
Citi lowers CBS target to $51, Viacom target to $22
Citi analyst Jason Bazinet lowered his price target on Buy-rated CBS (CBS) to $51 from $57 and on Neutral-rated Viacom (VIAB) to $22 from $29 following last week's S-4 filing that contained details related to the upcoming merger. Management projections suggest the combined company should deliver fairly flat EBITDA margins over the next few years, Bazinet tells investors in a research note. The Street, however, had been expecting EBITDA margin expansion in the coming years, says the analyst.

TODAY'S FREE FLY STORIES

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

07:19
12/09/19
12/09
07:19
12/09/19
07:19
Conference/Events
Autolus Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

SPCE

Virgin Galactic

$7.28

0.07 (0.97%)

07:17
12/09/19
12/09
07:17
12/09/19
07:17
Initiation
Virgin Galactic initiated  »

Morgan Stanley cites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

TCBI

Texas Capital

$57.82

0.76 (1.33%)

, IBTX

Independent Bank

$59.23

1 (1.72%)

07:15
12/09/19
12/09
07:15
12/09/19
07:15
Hot Stocks
Independent Bank, Texas Capital Bancshares enter $5.5B all-stock merger »

Texas Capital Bancshares…

TCBI

Texas Capital

$57.82

0.76 (1.33%)

IBTX

Independent Bank

$59.23

1 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

$41.25

0.11 (0.27%)

07:15
12/09/19
12/09
07:15
12/09/19
07:15
Recommendations
Zai Lab analyst commentary  »

Citi opens 'positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGI

Pattern Energy

$27.45

0.02 (0.07%)

07:14
12/09/19
12/09
07:14
12/09/19
07:14
Hot Stocks
Pattern Energy announces expiration of 'Go-Shop Period' »

Pattern Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$171.49

7.13 (4.34%)

07:12
12/09/19
12/09
07:12
12/09/19
07:12
Downgrade
3M rating change  »

Citi downgrades 3M to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

FTV

Fortive

$72.86

0.5 (0.69%)

, MMM

3M

$171.49

7.13 (4.34%)

07:11
12/09/19
12/09
07:11
12/09/19
07:11
Upgrade
Fortive, 3M rating change  »

Citi upgrades Fortive to…

FTV

Fortive

$72.86

0.5 (0.69%)

MMM

3M

$171.49

7.13 (4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

ORAN

Orange SA

$15.02

-0.055 (-0.36%)

07:10
12/09/19
12/09
07:10
12/09/19
07:10
Downgrade
Orange SA rating change  »

Orange SA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMDA

Kamada

$7.36

-0.025 (-0.34%)

07:10
12/09/19
12/09
07:10
12/09/19
07:10
Hot Stocks
Kamada enters into binding term sheet, sees product adding $8M-$10M in revenue »

Kamada announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

07:09
12/09/19
12/09
07:09
12/09/19
07:09
Hot Stocks
Canadian Solar authorizes $150M share repurchase program »

Canadian Solar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETNB

89bio

$28.38

0.86 (3.13%)

07:09
12/09/19
12/09
07:09
12/09/19
07:09
Initiation
89bio initiated  »

89bio initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONG

Akazoo

$5.40

-0.12 (-2.17%)

07:08
12/09/19
12/09
07:08
12/09/19
07:08
Earnings
Akazoo reports Q3 EPS EUR0.03 vs, EUR0.02 last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECC

Eagle Point Credit

$15.03

-0.01 (-0.07%)

07:08
12/09/19
12/09
07:08
12/09/19
07:08
Upgrade
Eagle Point Credit rating change  »

Eagle Point Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$122.36

1.6 (1.32%)

07:07
12/09/19
12/09
07:07
12/09/19
07:07
Conference/Events
Texas Instruments management to meet with UBS »

Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 16

    Dec

KALV

KalVista

$14.36

0.25 (1.77%)

, MRK

Merck

$88.84

0.09 (0.10%)

07:06
12/09/19
12/09
07:06
12/09/19
07:06
Hot Stocks
KalVista says KVD001 does not meet primary endpoint »

KalVista Pharmaceuticals…

KALV

KalVista

$14.36

0.25 (1.77%)

MRK

Merck

$88.84

0.09 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

VTNR

Vertex Energy

$1.59

(0.00%)

07:05
12/09/19
12/09
07:05
12/09/19
07:05
Initiation
Vertex Energy initiated  »

Vertex Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.20

-0.01 (-0.03%)

07:05
12/09/19
12/09
07:05
12/09/19
07:05
Conference/Events
AT&T management to meet with UBS »

Dinner Meeting with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

NOW

ServiceNow

$272.19

-0.94 (-0.34%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Conference/Events
ServiceNow management to meet with UBS »

Dinner Meeting with Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

RCKT

Rocket Pharmaceuticals

$22.37

2.61 (13.21%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Hot Stocks
Rocket Pharmaceuticals announces preliminary data from RP-L201 Phase 1/2 trial »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:03
12/09/19
12/09
07:03
12/09/19
07:03
Recommendations
Agios Pharmaceuticals analyst commentary  »

Cantor sees Agios trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

07:01
12/09/19
12/09
07:01
12/09/19
07:01
Recommendations
Agios Pharmaceuticals analyst commentary  »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

CI

Cigna

$198.96

3.44 (1.76%)

07:00
12/09/19
12/09
07:00
12/09/19
07:00
Conference/Events
Cigna management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 06

    Feb

AMAT

Applied Materials

$56.60

0.77 (1.38%)

06:59
12/09/19
12/09
06:59
12/09/19
06:59
Conference/Events
Applied Materials management to meet with UBS »

Breakfast Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CGC

Canopy Growth

$18.65

0.07 (0.38%)

, STZ

Constellation Brands

$183.60

1.13 (0.62%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Recommendations
Cantor sees over 66% chance of Constellation bidding for Canopy Growth »

Cantor Fitzgerald analyst…

CGC

Canopy Growth

$18.65

0.07 (0.38%)

STZ

Constellation Brands

$183.60

1.13 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

MTG

MGIC Investment

$14.10

-0.03 (-0.21%)

06:58
12/09/19
12/09
06:58
12/09/19
06:58
Hot Stocks
MGIC Investment issues November operating statistics »

MGIC Investment issued an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.